These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20405353)

  • 1. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.
    Villa V; Tonelli M; Thellung S; Corsaro A; Tasso B; Novelli F; Canu C; Pino A; Chiovitti K; Paludi D; Russo C; Sparatore A; Aceto A; Boido V; Sparatore F; Florio T
    Neurotox Res; 2011 May; 19(4):556-74. PubMed ID: 20405353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
    Dollinger S; Löber S; Klingenstein R; Korth C; Gmeiner P
    J Med Chem; 2006 Nov; 49(22):6591-5. PubMed ID: 17064077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231.
    Corsaro A; Thellung S; Chiovitti K; Villa V; Simi A; Raggi F; Paludi D; Russo C; Aceto A; Florio T
    Neurotox Res; 2009 Feb; 15(2):138-54. PubMed ID: 19384577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position.
    Nguyen T; Sakasegawa Y; Doh-Ura K; Go ML
    Eur J Med Chem; 2011 Jul; 46(7):2917-29. PubMed ID: 21531054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Korth C; May BC; Cohen FE; Prusiner SB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9836-41. PubMed ID: 11504948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.
    May BC; Fafarman AT; Hong SB; Rogers M; Deady LW; Prusiner SB; Cohen FE
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3416-21. PubMed ID: 12626750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
    Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
    OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231.
    Villa V; Corsaro A; Thellung S; Paludi D; Chiovitti K; Venezia V; Nizzari M; Russo C; Schettini G; Aceto A; Florio T
    Ann N Y Acad Sci; 2006 Dec; 1090():276-91. PubMed ID: 17384271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiprion activity of functionalized 9-aminoacridines related to quinacrine.
    Nguyen TH; Lee CY; Teruya K; Ong WY; Doh-ura K; Go ML
    Bioorg Med Chem; 2008 Jul; 16(14):6737-46. PubMed ID: 18556207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinacrine reactivity with prion proteins and prion-derived peptides.
    Zawada Z; Šafařík M; Dvořáková E; Janoušková O; Březinová A; Stibor I; Holada K; Bouř P; Hlaváček J; Sebestík J
    Amino Acids; 2013 May; 44(5):1279-92. PubMed ID: 23340659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments.
    Klingenstein R; Löber S; Kujala P; Godsave S; Leliveld SR; Gmeiner P; Peters PJ; Korth C
    J Neurochem; 2006 Aug; 98(3):748-59. PubMed ID: 16749906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acridin-9-yl exchange: a proposal for the action of some 9-aminoacridine drugs.
    Sebestík J; Safarík M; Stibor I; Hlavácek J
    Biopolymers; 2006; 84(6):605-14. PubMed ID: 16933221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein.
    Corsaro A; Thellung S; Bucciarelli T; Scotti L; Chiovitti K; Villa V; D'Arrigo C; Aceto A; Florio T
    Int J Biochem Cell Biol; 2011 Mar; 43(3):372-82. PubMed ID: 21094273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion inhibition with multivalent PrPSc binding compounds.
    Mays CE; Joy S; Li L; Yu L; Genovesi S; West FG; Westaway D
    Biomaterials; 2012 Oct; 33(28):6808-22. PubMed ID: 22748770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231.
    Corsaro A; Paludi D; Villa V; D'Arrigo C; Chiovitti K; Thellung S; Russo C; Di Cola D; Ballerini P; Patrone E; Schettini G; Aceto A; Florio T
    Int J Immunopathol Pharmacol; 2006; 19(2):339-56. PubMed ID: 16831301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibition of prion propagation by enantiomers of quinacrine.
    Ryou C; Legname G; Peretz D; Craig JC; Baldwin MA; Prusiner SB
    Lab Invest; 2003 Jun; 83(6):837-43. PubMed ID: 12808118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects.
    Chiovitti K; Corsaro A; Thellung S; Villa V; Paludi D; D'Arrigo C; Russo C; Perico A; Ianieri A; Di Cola D; Vergara A; Aceto A; Florio T
    J Neurochem; 2007 Dec; 103(6):2597-609. PubMed ID: 17944873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivity of 9-aminoacridine drug quinacrine with glutathione limits its antiprion activity.
    Šafařík M; Moško T; Zawada Z; Šafaříková E; Dračínský M; Holada K; Šebestík J
    Chem Biol Drug Des; 2017 Jun; 89(6):932-942. PubMed ID: 27933730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug metabolizing enzyme induction by benzoquinolines, acridine, and quinacrine; tricyclic aromatic molecules containing a single heterocyclic nitrogen.
    Le HT; Lamb JG; Franklin MR
    J Biochem Toxicol; 1996; 11(6):297-303. PubMed ID: 9176741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acridine derivatives activate p53 and induce tumor cell death through Bax.
    Wang W; Ho WC; Dicker DT; MacKinnon C; Winkler JD; Marmorstein R; El-Deiry WS
    Cancer Biol Ther; 2005 Aug; 4(8):893-8. PubMed ID: 16177561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.